221 results on '"Itokawa M"'
Search Results
2. Genome-wide association study identifies a potent locus associated with human opioid sensitivity
- Author
-
Nishizawa, D, Fukuda, K, Kasai, S, Hasegawa, J, Aoki, Y, Nishi, A, Saita, N, Koukita, Y, Nagashima, M, Katoh, R, Satoh, Y, Tagami, M, Higuchi, S, Ujike, H, Ozaki, N, Inada, T, Iwata, N, Sora, I, Iyo, M, Kondo, N, Won, M-J, Naruse, N, Uehara-Aoyama, K, Itokawa, M, Koga, M, Arinami, T, Kaneko, Y, Hayashida, M, and Ikeda, K
- Published
- 2014
- Full Text
- View/download PDF
3. Linkage disequilibrium and association with methamphetamine dependence/psychosis of μ-opioid receptor gene polymorphisms
- Author
-
Ide, S, Kobayashi, H, Ujike, H, Ozaki, N, Sekine, Y, Inada, T, Harano, M, Komiyama, T, Yamada, M, Iyo, M, Iwata, N, Tanaka, K, Shen, H, Iwahashi, K, Itokawa, M, Minami, M, Satoh, M, Ikeda, K, and Sora, I
- Published
- 2006
- Full Text
- View/download PDF
4. Schizophrenia with the 22q11.2 deletion and additional genetic defects: case history
- Author
-
Toyosima, M., Maekawa, M., Toyota, T., Iwayama, Y., Arai, M., Ichikawa, T., Miyashita, M., Arinami, T., Itokawa, M., and Yoshikawa, T.
- Published
- 2011
5. Psychotic-like experiences are associated with suicidal feelings and deliberate self-harm behaviors in adolescents aged 12–15 years
- Author
-
Nishida, A., Sasaki, T., Nishimura, Y., Tanii, H., Hara, N., Inoue, K., Yamada, T., Takami, T., Shimodera, S., Itokawa, M., Asukai, N., and Okazaki, Y.
- Published
- 2010
- Full Text
- View/download PDF
6. Two-step association analyses of the chromosome 18p11.2 region in schizophrenia detect a locus encompassing C18orf1
- Author
-
Kikuchi, M, Yamada, K, Toyota, T, Itokawa, M, Hattori, E, Yoshitsugu, K, Shimizu, H, and Yoshikawa, T
- Published
- 2003
- Full Text
- View/download PDF
7. Excess hydrogen sulfide and polysulfides production underlies a schizophrenia pathophysiology
- Author
-
Ide, M, Ohnishi, T, Toyoshima, M, Balan, S, Maekawa, M, Shimamoto-Mitsuyama, C, Iwayama, Y, Ohba, H, Watanabe, A, Ishii, T, Shibuya, N, Kimura, Y, Hisano, Y, Murata, Y, Hara, T, Morikawa, M, Hashimoto, K, Nozaki, Y, Toyota, T, Wada, Y, Tanaka, Y, Kato, T, Nishi, A, Fujisawa, S, Okano, H, Itokawa, M, Hirokawa, N, Kunii, Y, Kakita, A, Yabe, H, Iwamoto, K, Meno, K, Katagiri, T, Dean, B, Uchida, K, Kimura, H, Yoshikawa, T, Ide, M, Ohnishi, T, Toyoshima, M, Balan, S, Maekawa, M, Shimamoto-Mitsuyama, C, Iwayama, Y, Ohba, H, Watanabe, A, Ishii, T, Shibuya, N, Kimura, Y, Hisano, Y, Murata, Y, Hara, T, Morikawa, M, Hashimoto, K, Nozaki, Y, Toyota, T, Wada, Y, Tanaka, Y, Kato, T, Nishi, A, Fujisawa, S, Okano, H, Itokawa, M, Hirokawa, N, Kunii, Y, Kakita, A, Yabe, H, Iwamoto, K, Meno, K, Katagiri, T, Dean, B, Uchida, K, Kimura, H, and Yoshikawa, T
- Abstract
Mice with the C3H background show greater behavioral propensity for schizophrenia, including lower prepulse inhibition (PPI), than C57BL/6 (B6) mice. To characterize as-yet-unknown pathophysiologies of schizophrenia, we undertook proteomics analysis of the brain in these strains, and detected elevated levels of Mpst, a hydrogen sulfide (H2 S)/polysulfide-producing enzyme, and greater sulfide deposition in C3H than B6 mice. Mpst-deficient mice exhibited improved PPI with reduced storage sulfide levels, while Mpst-transgenic (Tg) mice showed deteriorated PPI, suggesting that "sulfide stress" may be linked to PPI impairment. Analysis of human samples demonstrated that the H2 S/polysulfides production system is upregulated in schizophrenia. Mechanistically, the Mpst-Tg brain revealed dampened energy metabolism, while maternal immune activation model mice showed upregulation of genes for H2 S/polysulfides production along with typical antioxidative genes, partly via epigenetic modifications. These results suggest that inflammatory/oxidative insults in early brain development result in upregulated H2 S/polysulfides production as an antioxidative response, which in turn cause deficits in bioenergetic processes. Collectively, this study presents a novel aspect of the neurodevelopmental theory for schizophrenia, unraveling a role of excess H2 S/polysulfides production.
- Published
- 2019
8. Identification of an argpyrimidine-modified protein in human red blood cells from schizophrenic patients: A possible biomarker for diseases involving carbonyl stress
- Author
-
Ishida, Y.I., primary, Kayama, T., additional, Kibune, Y., additional, Nishimoto, S., additional, Koike, S., additional, Suzuki, T., additional, Horiuchi, Y., additional, Miyashita, M., additional, Itokawa, M., additional, Arai, M., additional, and Ogasawara, Y., additional
- Published
- 2017
- Full Text
- View/download PDF
9. A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder
- Author
-
Ikeda, M, Takahashi, A, Kamatani, Y, Okahisa, Y, Kunugi, H, Mori, N, Sasaki, T, Ohmori, Tetsuro, Okamoto, Y, Kawasaki, H, Shimodera, S, Kato, T, Yoneda, H, Yoshimura, R, Iyo, M, Matsuda, K, Akiyama, M, Ashikawa, K, Kashiwase, K, Tokunaga, K, Kondo, K, Saito, T, Shimasaki, A, Kawase, K, Kitajima, T, Matsuo, K, Itokawa, M, Someya, T, Inada, T, Hashimoto, R, Inoue, T, Akiyama, K, Tanii, H, Arai, H, Kanba, S, Ozaki, N, Kusumi, I, Yoshikawa, T, Kubo, M, Iwata, N, Ikeda, M, Takahashi, A, Kamatani, Y, Okahisa, Y, Kunugi, H, Mori, N, Sasaki, T, Ohmori, Tetsuro, Okamoto, Y, Kawasaki, H, Shimodera, S, Kato, T, Yoneda, H, Yoshimura, R, Iyo, M, Matsuda, K, Akiyama, M, Ashikawa, K, Kashiwase, K, Tokunaga, K, Kondo, K, Saito, T, Shimasaki, A, Kawase, K, Kitajima, T, Matsuo, K, Itokawa, M, Someya, T, Inada, T, Hashimoto, R, Inoue, T, Akiyama, K, Tanii, H, Arai, H, Kanba, S, Ozaki, N, Kusumi, I, Yoshikawa, T, Kubo, M, and Iwata, N
- Abstract
Genome-wide association studies (GWASs) have identified several susceptibility loci for bipolar disorder (BD) and shown that the genetic architecture of BD can be explained by polygenicity, with numerous variants contributing to BD. In the present GWAS (Phase I/II), which included 2964 BD and 61 887 control subjects from the Japanese population, we detected a novel susceptibility locus at 11q12.2 (rs28456, P=6.4 × 10−9), a region known to contain regulatory genes for plasma lipid levels (FADS1/2/3). A subsequent meta-analysis of Phase I/II and the Psychiatric GWAS Consortium for BD (PGC-BD) identified another novel BD gene, NFIX (P best=5.8 × 10−10), and supported three regions previously implicated in BD susceptibility: MAD1L1 (P best=1.9 × 10−9), TRANK1 (P best=2.1 × 10−9) and ODZ4 (P best=3.3 × 10−9). Polygenicity of BD within Japanese and trans-European-Japanese populations was assessed with risk profile score analysis. We detected higher scores in BD cases both within (Phase I/II) and across populations (Phase I/II and PGC-BD). These were defined by (1) Phase II as discovery and Phase I as target, or vice versa (for ‘within Japanese comparisons’, Pbest~10−29, R2~2%), and (2) European PGC-BD as discovery and Japanese BD (Phase I/II) as target (for ‘trans-European-Japanese comparison,’ Pbest~10−13, R2~0.27%). This ‘trans population’ effect was supported by estimation of the genetic correlation using the effect size based on each population (liability estimates~0.7). These results indicate that (1) two novel and three previously implicated loci are significantly associated with BD and that (2) BD ‘risk’ effect are shared between Japanese and European populations.
- Published
- 2017
10. Estimating the resolution of real images
- Author
-
Mizutani, R, primary, Saiga, R, additional, Takekoshi, S, additional, Inomoto, C, additional, Nakamura, N, additional, Arai, M, additional, Oshima, K, additional, Itokawa, M, additional, Takeuchi, A, additional, Uesugi, K, additional, Terada, Y, additional, and Suzuki, Y, additional
- Published
- 2017
- Full Text
- View/download PDF
11. High-resolution copy number variation analysis of schizophrenia in Japan
- Author
-
Kushima, I, primary, Aleksic, B, additional, Nakatochi, M, additional, Shimamura, T, additional, Shiino, T, additional, Yoshimi, A, additional, Kimura, H, additional, Takasaki, Y, additional, Wang, C, additional, Xing, J, additional, Ishizuka, K, additional, Oya-Ito, T, additional, Nakamura, Y, additional, Arioka, Y, additional, Maeda, T, additional, Yamamoto, M, additional, Yoshida, M, additional, Noma, H, additional, Hamada, S, additional, Morikawa, M, additional, Uno, Y, additional, Okada, T, additional, Iidaka, T, additional, Iritani, S, additional, Yamamoto, T, additional, Miyashita, M, additional, Kobori, A, additional, Arai, M, additional, Itokawa, M, additional, Cheng, M -C, additional, Chuang, Y -A, additional, Chen, C -H, additional, Suzuki, M, additional, Takahashi, T, additional, Hashimoto, R, additional, Yamamori, H, additional, Yasuda, Y, additional, Watanabe, Y, additional, Nunokawa, A, additional, Someya, T, additional, Ikeda, M, additional, Toyota, T, additional, Yoshikawa, T, additional, Numata, S, additional, Ohmori, T, additional, Kunimoto, S, additional, Mori, D, additional, Iwata, N, additional, and Ozaki, N, additional
- Published
- 2016
- Full Text
- View/download PDF
12. The Piccolo Intronic Single Nucleotide Polymorphism rs13438494 Regulates Dopamine and Serotonin Uptake and Shows Associations with Dependence-Like Behavior in Genomic Association Study
- Author
-
Uno, K., primary, Nishizawa, D., additional, Seo, S., additional, Takayama, K., additional, Matsumura, S., additional, Sakai, N., additional, Ohi, K., additional, Nabeshima, T., additional, Hashimoto, R., additional, Ozaki, N., additional, Hasegawa, J., additional, Sato, N., additional, Tanioka, F., additional, Sugimura, H., additional, Fukuda, K.-I.-, additional, Higuchi, S., additional, Ujike, H., additional, Inada, T., additional, Iwata, N., additional, Sora, I., additional, Iyo, M., additional, Kondo, N., additional, Won, M.-J., additional, Naruse, N., additional, Uehara-Aoyama, K., additional, Itokawa, M., additional, Yamada, M., additional, Ikeda, K., additional, Miyamoto, Y., additional, and Nitta, A., additional
- Published
- 2015
- Full Text
- View/download PDF
13. A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder
- Author
-
Ikeda, M, Takahashi, A, Kamatani, Y, Okahisa, Y, Kunugi, H, Mori, N, Sasaki, T, Ohmori, T, Okamoto, Y, Kawasaki, H, Shimodera, S, Kato, T, Yoneda, H, Yoshimura, R, Iyo, M, Matsuda, K, Akiyama, M, Ashikawa, K, Kashiwase, K, Tokunaga, K, Kondo, K, Saito, T, Shimasaki, A, Kawase, K, Kitajima, T, Matsuo, K, Itokawa, M, Someya, T, Inada, T, Hashimoto, R, Inoue, T, Akiyama, K, Tanii, H, Arai, H, Kanba, S, Ozaki, N, Kusumi, I, Yoshikawa, T, Kubo, M, and Iwata, N
- Abstract
Genome-wide association studies (GWASs) have identified several susceptibility loci for bipolar disorder (BD) and shown that the genetic architecture of BD can be explained by polygenicity, with numerous variants contributing to BD. In the present GWAS (Phase I/II), which included 2964 BD and 61 887 control subjects from the Japanese population, we detected a novel susceptibility locus at 11q12.2 (rs28456, P=6.4 × 10−9), a region known to contain regulatory genes for plasma lipid levels (FADS1/2/3). A subsequent meta-analysis of Phase I/II and the Psychiatric GWAS Consortium for BD (PGC-BD) identified another novel BD gene, NFIX (Pbest=5.8 × 10−10), and supported three regions previously implicated in BD susceptibility: MAD1L1 (Pbest=1.9 × 10−9), TRANK1 (Pbest=2.1 × 10−9) and ODZ4 (Pbest=3.3 × 10−9). Polygenicity of BD within Japanese and trans-European-Japanese populations was assessed with risk profile score analysis. We detected higher scores in BD cases both within (Phase I/II) and across populations (Phase I/II and PGC-BD). These were defined by (1) Phase II as discovery and Phase I as target, or vice versa (for ‘within Japanese comparisons’, Pbest~10−29, R2~2%), and (2) European PGC-BD as discovery and Japanese BD (Phase I/II) as target (for ‘trans-European-Japanese comparison,’ Pbest~10−13, R2~0.27%). This ‘trans population’ effect was supported by estimation of the genetic correlation using the effect size based on each population (liability estimates~0.7). These results indicate that (1) two novel and three previously implicated loci are significantly associated with BD and that (2) BD ‘risk’ effect are shared between Japanese and European populations.
- Published
- 2018
- Full Text
- View/download PDF
14. Genome-wide association study identifies a potent locus associated with human opioid sensitivity
- Author
-
Nishizawa, D, primary, Fukuda, K, additional, Kasai, S, additional, Hasegawa, J, additional, Aoki, Y, additional, Nishi, A, additional, Saita, N, additional, Koukita, Y, additional, Nagashima, M, additional, Katoh, R, additional, Satoh, Y, additional, Tagami, M, additional, Higuchi, S, additional, Ujike, H, additional, Ozaki, N, additional, Inada, T, additional, Iwata, N, additional, Sora, I, additional, Iyo, M, additional, Kondo, N, additional, Won, M-J, additional, Naruse, N, additional, Uehara-Aoyama, K, additional, Itokawa, M, additional, Koga, M, additional, Arinami, T, additional, Kaneko, Y, additional, Hayashida, M, additional, and Ikeda, K, additional
- Published
- 2012
- Full Text
- View/download PDF
15. Family‐based association study of schizophrenia with 444 markers and analysis of a new susceptibility locus mapped to 11q13.3
- Author
-
Yamada, K., primary, Iwayama‐Shigeno, Y., additional, Yoshida, Y., additional, Toyota, T., additional, Itokawa, M., additional, Hattori, E., additional, Shimizu, H., additional, and Yoshikawa, T., additional
- Published
- 2004
- Full Text
- View/download PDF
16. 1P-0080 Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis
- Author
-
Watanabe, T., primary, Itokawa, M., additional, and Katagiri, T., additional
- Published
- 2003
- Full Text
- View/download PDF
17. 3P-0904 Small dense low-density lipoprotein and carotid atherosclerosis in relation to vascular dementia
- Author
-
Watanabe, T., primary, Itokawa, M., additional, Koba, S., additional, and Katagiri, T., additional
- Published
- 2003
- Full Text
- View/download PDF
18. Evidence supporting an association between the DRB1 gene and schizophrenia in Japanese
- Author
-
Arinami, T, primary, Otsuka, Y, additional, Hamaguchi, H, additional, Itokawa, M, additional, Aoki, J, additional, Shibuya, H, additional, Okubo, Y, additional, Iwawaki, A, additional, Ota, K, additional, Enguchi, H, additional, Tagaya, H, additional, Yano, S, additional, Shimizu, H, additional, and Toru, M, additional
- Published
- 1998
- Full Text
- View/download PDF
19. Failure to find associations of the CA repeat polymorphism in the first intron and the Gly−63/Glu−63 polymorphism of the neurotrophin-3 gene with schizophrenia
- Author
-
Arinami, T., primary, Takekoshi, K., additional, Itokawa, M., additional, Hamaguchi, H., additional, and Toru, M., additional
- Published
- 1996
- Full Text
- View/download PDF
20. Association of dopamine D2 receptor molecular variant with schizophrenia
- Author
-
Arinami, T., primary, Hamaguchi, H., additional, Itokawa, M., additional, Enguchi, H., additional, Tagaya, H., additional, Yano, S., additional, Toru, M., additional, and Shimizu, H., additional
- Published
- 1994
- Full Text
- View/download PDF
21. A Structural Polymorphism of Human Dopamine D2 Receptor D2(Ser311 → Cys)
- Author
-
Itokawa, M., primary, Arinami, T., additional, Futamura, N., additional, Hamaguchi, H., additional, and Toru, M., additional
- Published
- 1993
- Full Text
- View/download PDF
22. Failure to find associations of the CA repeat polymorphism in the first intron and the Gly-63/Glu-63 polymorphism of the neurotrophin-3 gene with schizophrenia.
- Author
-
Arinami, T., Takekoshi, K., Itokawa, M., Hamaguchi, H., and Toru, M.
- Published
- 1996
23. A Structural Polymorphism of Human Dopamine D2 Receptor D2(Ser311 → Cys)
- Author
-
Itokawa, M., Arinami, T., Futamura, N., Hamaguchi, H., and Toru, M.
- Abstract
No structural change of the dopamine D2 receptor (DRD2) has been reported so far, though the DRD2 gene has been suggested to be one of the candidate genes for mental disorders. Herein we report one missense nucleotide mutation from C to G resulting in a substitution of serine with cystein at the codon 311 located in the third intracellular loop of the DRD2 that was found in the analyses of the sequence of the DRD2 gene in 50 schizophrenics. The allele frequency, 0.04, of this Cys
311 allele in 50 schizophrenics was slightly increased compared with that, 0.023, in 110 controls though the difference was not significant. The schizophrenics with Cys311 tended to have a lower age of onset and a positive family history of schizophrenia.Copyright 1993, 1999 Academic Press- Published
- 1993
- Full Text
- View/download PDF
24. Failure to find associations of the CA repeat polymorphism in the first intron and the Gly−63Glu−63polymorphism of the neurotrophin3 gene with schizophrenia
- Author
-
Arinami, T., Takekoshi, K., Itokawa, M., Hamaguchi, H., and Toru, M.
- Abstract
This study aimed to replicate positive associations between polymorphisms of the neurotrophin-3 gene and schizophrenia. The reported associations, which were the results of searching for mutations in the locus in schizophrenics under the hypothesis of neurodevelopmental etiology of schizophrenia, are that the states carrying the (CA)23allele of the CA repeat in the first intron have a 2.56-fold increased risk of schizophrenia and those carrying the allele Glu-63instead of Gly-63have a 2.6-fold increased risk of schizophrenia with onset before 25 years and with duration of the illness of more than 10 years. We analyzed these polymorphisms in 80 schizophrenics with onset before 25 years of age and with duration of illness of more than 10 years and 80 age-matched psychosis-free controls. With our sample size, there was a 90 chance of detecting odds ratios observed in initial positive reports. We found similar allele and genotype frequencies of both polymorphisms between the schizophrenic and control groups. We failed to support associations between the polymorphisms of the neurotrophin-3 gene analyzed and schizophrenia.
- Published
- 1996
25. Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia
- Author
-
Ishiguro, H., Ohtsuki, T., Toru, M., Itokawa, M., Aoki, J., Shibuya, H., Kurumaji, A., Okubo, Y., Iwawaki, A., and Ota, K.
- Published
- 1998
- Full Text
- View/download PDF
26. Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells.
- Author
-
Itokawa, M, Toru, M, Ito, K, Tsuga, H, Kameyama, K, Haga, T, Arinami, T, and Hamaguchi, H
- Abstract
The short (D2S) and long (D2L) isoforms of dopamine D2 receptors were stably expressed in Chinese hamster ovary cells, and dopamine-induced sequestration was examined by measuring the loss of binding of the hydrophilic ligand [3H]sulpiride from the cell surface. Dopamine treatment of Chinese hamster ovary cells expressing D2S for 30 min at 37 degrees caused a 43.8 +/- 3.4% decrease in [3H]sulpiride binding activity measured by incubation of the treated cells with [3H]sulpiride at 4 degrees for 4 hr after the dopamine was washed out. The half-life of the decrease in binding was estimated to be 18.7 +/- 1.6 min, and the concentration of dopamine giving a half-maximal effect (EC50) was estimated to be 180 +/- 90 nM. The decrease was reversible, and the binding activity was recovered by washing out the dopamine and incubating the cells at 37 degrees for 30 min but was not reversible when the cells were incubated at 4 degrees. The binding activity of [3H]spiperone, a hydrophobic ligand, was not affected by the dopamine treatment under the same experimental conditions. These results indicate that approximately one half of the D2S receptors undergo agonist-induced sequestration, probably endocytosis, in a reversible and temperature-dependent manner. Sequestration of D2L receptors was not as apparent as that of D2S receptors; the decrease in [3H]sulpiride binding activity was 21.6 +/- 0.9% and the rate of the decrease was delayed, with a half-life of 33.2 +/- 7.8 min, although effective concentrations of dopamine were similar, with EC50 = 170 +/- 50 nM. A D2S receptor variant containing a missense mutation changing Ser311 in the third intracellular loop to cysteine was found to be sequestered to a significantly lesser extent than with wild-type D2S receptors. This finding was discussed with respect to the report that this variant gene is found more frequently in schizophrenic patients than in control subjects.
- Published
- 1996
27. An Insertion/Deletion Polymorphism in the Angiotensin Converting Enzyme Gene Is Associated with Both Brain Substance P Contents and Affective Disorders
- Author
-
Arinami, T., Li, L., Mitsushio, H., Itokawa, M., Hamaguchi, H., and Toru, M.
- Published
- 1996
- Full Text
- View/download PDF
28. Paradox of schizophrenia genetics: is a paradigm shift occurring?
- Author
-
Doi Nagafumi, Hoshi Yoko, Itokawa Masanari, Yoshikawa Takeo, Ichikawa Tomoe, Arai Makoto, Usui Chie, and Tachikawa Hirokazu
- Subjects
Mutation-selection balance ,Heterozygote advantage ,Sex difference ,MtDNA ,Gene-gene interaction ,Gene-environment interaction ,Protective gene ,Mitochondrial dysfunction ,Oxidative stress ,Genomic instability ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background Genetic research of schizophrenia (SCZ) based on the nuclear genome model (NGM) has been one of the most active areas in psychiatry for the past two decades. Although this effort is ongoing, the current situation of the molecular genetics of SCZ seems disappointing or rather perplexing. Furthermore, a prominent discrepancy between persistence of the disease at a relatively high prevalence and a low reproductive fitness of patients creates a paradox. Heterozygote advantage works to sustain the frequency of a putative susceptibility gene in the mitochondrial genome model (MGM) but not in the NGM. Methods We deduced a criterion that every nuclear susceptibility gene for SCZ should fulfill for the persistence of the disease under general assumptions of the multifactorial threshold model. SCZ-associated variants listed in the top 45 in the SZGene Database (the version of the 23rd December, 2011) were selected, and the distribution of the genes that could meet or do not meet the criterion was surveyed. Results 19 SCZ-associated variants that do not meet the criterion are located outside the regions where the SCZ-associated variants that could meet the criterion are located. Since a SCZ-associated variant that does not meet the criterion cannot be a susceptibility gene, but instead must be a protective gene, it should be linked to a susceptibility gene in the NGM, which is contrary to these results. On the other hand, every protective gene on any chromosome can be associated with SCZ in the MGM. Based on the MGM we propose a new hypothesis that assumes brain-specific antioxidant defenses in which trans-synaptic activations of dopamine- and N-methyl-d-aspartate-receptors are involved. Most of the ten predictions of this hypothesis seem to accord with the major epidemiological facts and the results of association studies to date. Conclusion The central paradox of SCZ genetics and the results of association studies to date argue against the NGM, and in its place the MGM is emerging as a viable option to account for genomic and pathophysiological research findings involving SCZ.
- Published
- 2012
- Full Text
- View/download PDF
29. The adenosine A2A receptor is associated with methamphetamine dependence/psychosis in the Japanese population
- Author
-
Kobayashi Hideaki, Ujike Hiroshi, Iwata Nakao, Inada Toshiya, Yamada Mitsuhiko, Sekine Yoshimoto, Uchimura Naohisa, Iyo Masaomi, Ozaki Norio, Itokawa Masanari, and Sora Ichiro
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background Several lines of evidence suggest that the dopaminergic nervous system contributes to methamphetamine (METH) dependence, and there is increasing evidence of antagonistic interactions between dopamine and adenosine receptors. We therefore hypothesized that variations in the A2A adenosine receptor (ADORA2A) gene modify genetic susceptibility to METH dependence/psychosis. Methods We first analyzed variations in the exons and exon-intron boundaries of the ADORA2A gene in METH dependent/psychotic patients. Then an association analysis between these single nucleotide polymorphisms and METH dependence/psychosis was performed using a total of 171 METH dependent/psychotic patients and 229 controls. Results We found 6 variations, of which one single nucleotide polymorphism (SNP) was novel. Significant associations were observed between the allelic and genotypic frequencies of the Exon2+751 (rs5751876) SNP and METH dependence/psychosis. These associations were observed especially in females. In the clinical feature analyses, significant associations were observed between the SNP and the patient subgroup using METH alone (i.e., without concomitant use of other substances of abuse). Conclusions These results suggest that the ADORA2A gene could be a vulnerability factor for METH dependence/psychosis, especially in females and/or in patients using only METH.
- Published
- 2010
- Full Text
- View/download PDF
30. Association between Severity of Alcoholism and the Al Allele of the Dopamine D2 Receptor Gene TaqI A RFLP in Japanese
- Author
-
Arinami, T., Itokawa, M., Komiyama, T., and Mitsushio, H.
- Published
- 1993
- Full Text
- View/download PDF
31. Advanced glycation end products and schizophrenia: A systematic review.
- Author
-
Kouidrat, Y., Amad, A., Arai, M., Miyashita, M., Lalau, J. D., Loas, G., and Itokawa, M.
- Subjects
- *
ADVANCED glycation end-products , *DIAGNOSIS of schizophrenia , *OXIDATIVE stress , *BIOMARKERS , *DISEASE progression , *SYSTEMATIC reviews - Abstract
Oxidative stress has become an exciting area of research on schizophrenia, which is a highly prevalent condition that affects approximately 1% of the worldwide population. Advanced glycation end products (AGEs), which are considered metabolic biomarkers of increased oxidative stress, have a pathogenic role in the development and progression of different oxidative stress-based diseases including atherosclerosis, diabetes, neurodegenerative disorders and schizophrenia. AGE formation and accumulation as well as the activation of its receptor (RAGE) can lead to signaling through several inflammatory signaling pathways and further damaging effects. This systematic review is based on a search conducted in July 2014 in which 6 studies were identified that met our criteria. In this work, we describe how recent methodological advances regarding the role of AGEs may contribute to a better understanding of the pathophysiology of schizophrenia and provide a different approach in the comprehension of the relationship between cardiovascular disease and schizophrenia. These latest findings may lead to new directions for future research on novel diagnostic and treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
32. Failure to find an association between myosin heavy chain 9, non-muscle (MYH9) and schizophrenia: a three-stage case-control association study.
- Author
-
Amagane H, Watanabe Y, Kaneko N, Nunokawa A, Muratake T, Ishiguro H, Arinami T, Ujike H, Inada T, Iwata N, Kunugi H, Sasaki T, Hashimoto R, Itokawa M, Ozaki N, Someya T, Amagane, Hideki, Watanabe, Yuichiro, Kaneko, Naoshi, and Nunokawa, Ayako
- Abstract
Several genome-wide linkage studies have suggested linkage between markers on the long arm of chromosome 22 and schizophrenia. It has also been reported that 22q11.2 deletions increase the risk of schizophrenia. Therefore, 22q is a candidate region for schizophrenia. To search for genetic susceptibility loci for schizophrenia on 22q, we conducted a three-stage case-control association study in Japanese individuals. In the first stage, we examined 13 microsatellite markers on 22q in 766 individuals (340 patients with schizophrenia and 426 control individuals) and found a potential association of AFM262VH5 (D22S283) with schizophrenia. In the second stage, we performed fine mapping of the myosin heavy chain 9, non-muscle (MYH9) gene, where AFM262VH5 is located, using 25 tagging single nucleotide polymorphisms (SNPs). We obtained potential associations between three SNPs in MYH9 and schizophrenia in 1193 individuals (595 patients and 598 controls), which included the individuals analyzed in the first stage. In the third stage, however, we could not replicate these associations in 4694 independent individuals (2288 patients and 2406 controls). Our results suggest that MYH9 does not confer increased susceptibility to schizophrenia in the Japanese population, although we could not exclude possible contributions of other genes on 22q to the pathogenesis of schizophrenia. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
33. The dopamine D3 receptor (DRD3) gene and risk of schizophrenia: case-control studies and an updated meta-analysis.
- Author
-
Nunokawa A, Watanabe Y, Kaneko N, Sugai T, Yazaki S, Arinami T, Ujike H, Inada T, Iwata N, Kunugi H, Sasaki T, Itokawa M, Ozaki N, Hashimoto R, Someya T, Nunokawa, Ayako, Watanabe, Yuichiro, Kaneko, Naoshi, Sugai, Takuro, and Yazaki, Saori
- Abstract
The dopamine D3 receptor (DRD3) has been suggested to be involved in the pathophysiology of schizophrenia. DRD3 has been tested for an association with schizophrenia, but with conflicting results. A recent meta-analysis suggested that the haplotype T-T-T-G for the SNPs rs7631540-rs1486012-rs2134655-rs963468 may confer protection against schizophrenia. However, almost all previous studies of the association between DRD3 and schizophrenia have been performed using a relatively small sample size and a limited number of markers. To assess whether DRD3 is implicated in vulnerability to schizophrenia, we conducted case-control association studies and performed an updated meta-analysis. In the first population (595 patients and 598 controls), we examined 16 genotyped single nucleotide polymorphisms (SNPs), including tagging SNPs selected from the HapMap database and SNPs detected through resequencing, as well as 58 imputed SNPs that are not directly genotyped. To confirm the results obtained, we genotyped the SNPs rs7631540-rs1486012-rs2134655-rs963468 in a second, independent population (2126 patients and 2228 controls). We also performed an updated meta-analysis of the haplotype, combining the results obtained in five populations, with a total sample size of 7551. No supportive evidence was obtained for an association between DRD3 and schizophrenia in our Japanese subjects. Our updated meta-analysis also failed to confirm the existence of a protective haplotype. To draw a definitive conclusion, further studies using larger samples and sufficient markers should be carried out in various ethnic populations. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
34. A two-stage case-control association study between the tryptophan hydroxylase 2 (TPH2) gene and schizophrenia in a Japanese population.
- Author
-
Watanabe Y, Egawa J, Iijima Y, Nunokawa A, Kaneko N, Shibuya M, Arinami T, Ujike H, Inada T, Iwata N, Tochigi M, Kunugi H, Itokawa M, Ozaki N, Hashimoto R, Someya T, Watanabe, Yuichiro, Egawa, Jun, Iijima, Yoshimi, and Nunokawa, Ayako
- Published
- 2012
- Full Text
- View/download PDF
35. Copy number variations in RNF216 and postsynaptic membrane-associated genes are associated with bipolar disorder: a case-control study in the Japanese population.
- Author
-
Nakatochi M, Kushima I, Aleksic B, Kimura H, Kato H, Inada T, Torii Y, Takahashi N, Yamamoto M, Iwamoto K, Nawa Y, Iritani S, Iwata N, Saito T, Ninomiya K, Okochi T, Hashimoto R, Yamamori H, Yasuda Y, Fujimoto M, Miura K, Ohi K, Shioiri T, Kitaichi K, Itokawa M, Arai M, Miyashita M, Toriumi K, Takahashi T, Suzuki M, Kato TA, Kanba S, Horikawa H, Kasai K, Ikegame T, Jinde S, Kato T, Kakiuchi C, Yamagata B, Nio S, Kunii Y, Yabe H, Okamura Y, Tadaka S, Fumihiko U, Obara T, Yamamoto Y, Arioka Y, Mori D, Ikeda M, and Ozaki N
- Abstract
Aim: Bipolar disorder (BD) is a common psychiatric disorder characterized by alterations between manic/hypomanic and depressive states. Rare pathogenic copy number variations (CNVs) that overlap with exons of synaptic genes have been associated with BD. However, no study has comprehensively explored CNVs in synaptic genes associated with BD. Here, we evaluated the relationship between BD and rare CNVs that overlap with synaptic genes, not limited to exons, in the Japanese population., Methods: Using array comparative genome hybridization, we detected CNVs in 1839 patients with BD and 2760 controls. We used the Synaptic Gene Ontology database to identify rare CNVs that overlap with synaptic genes. Using gene-based analysis, we compared their frequencies between the BD and control groups. We also searched for synaptic gene sets related to BD. The significance level was set to a false discovery rate of 10%., Results: The RNF216 gene was significantly associated with BD (odds ratio, 4.51 [95% confidence interval, 1.66-14.89], false discovery rate < 10%). The BD-associated CNV that corresponded with RNF216 also partially overlapped with the minimal critical region of the 7p22.1 microduplication syndrome. The integral component of the postsynaptic membrane (Gene Ontology:0099055) was significantly associated with BD. The CNV overlapping with the intron region of GRM5 in this gene set showed a nominal significant association between cases and controls (P < 0.05)., Conclusion: We provide evidence that CNVs in RNF216 and postsynaptic membrane-related genes confer a risk of BD, contributing to a better understanding of the pathogenesis of BD., (© 2024 The Author(s). Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.)
- Published
- 2024
- Full Text
- View/download PDF
36. Amyloban, extracted from Hericium erinaceus, ameliorates social deficits and suppresses the enhanced dopaminergic system in social defeat stress mice.
- Author
-
Wang T, Toriumi K, Suzuki K, Miyashita M, Ozawa A, Masada M, Itokawa M, and Arai M
- Abstract
Social dysfunctions are common in various psychiatric disorders, including depression, schizophrenia, and autism, and are long-lasting and difficult to treat. The development of treatments for social impairment is critical for the treatment of several psychiatric disorders. "Amyloban 3399," a product extracted from the mushroom Hericium erinaceus, markedly improves social dysfunctions in patients with treatment-resistant schizophrenia and depression. However, the molecular mechanism(s) through which amyloban ameliorates social impairment remains unclear. To clarify this mechanism, in this study, we aimed to establish a mouse model of social defeat stress (SDS) and investigate the effects of amyloban on social deficits. Amyloban administration ameliorated social deficits and the dopamine system activity in SDS mice. These findings suggest that there is a possibility that amyloban may improve social deficits by suppressing the hyperactivation of the dopaminergic system. Amyloban may be an effective treatment for social dysfunctions associated with various psychiatric disorders., (© 2024 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.)
- Published
- 2024
- Full Text
- View/download PDF
37. Association of homocysteine with white matter dysconnectivity in schizophrenia.
- Author
-
Tabata K, Son S, Miyata J, Toriumi K, Miyashita M, Suzuki K, Itokawa M, Takahashi H, Murai T, and Arai M
- Abstract
Several studies have shown white matter (WM) dysconnectivity in people with schizophrenia (SZ). However, the underlying mechanism remains unclear. We investigated the relationship between plasma homocysteine (Hcy) levels and WM microstructure in people with SZ using diffusion tensor imaging (DTI). Fifty-three people with SZ and 83 healthy controls (HC) were included in this retrospective observational study. Tract-Based Spatial Statistics (TBSS) were used to evaluate group differences in WM microstructure. A significant negative correlation between plasma Hcy levels and WM microstructural disruption was noted in the SZ group (Spearman's ρ = -.330, P = 0.016) but not in the HC group (Spearman's ρ = .041, P = 0.712). These results suggest that increased Hcy may be associated with WM dysconnectivity in SZ, and the interaction between Hcy and WM dysconnectivity could be a potential mechanism of the pathophysiology of SZ. Further, longitudinal studies are required to investigate whether high Hcy levels subsequently cause WM microstructural disruption in people with SZ., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
38. Association between copy number variations in parkin (PRKN) and schizophrenia and autism spectrum disorder: A case-control study.
- Author
-
Lo T, Kushima I, Kimura H, Aleksic B, Okada T, Kato H, Inada T, Nawa Y, Torii Y, Yamamoto M, Kimura R, Funabiki Y, Kosaka H, Numata S, Kasai K, Sasaki T, Yokoyama S, Munesue T, Hashimoto R, Yasuda Y, Fujimoto M, Usami M, Itokawa M, Arai M, Ohi K, Someya T, Watanabe Y, Egawa J, Takahashi T, Suzuki M, Yamasue H, Iwata N, Ikeda M, and Ozaki N
- Subjects
- Humans, Case-Control Studies, Comparative Genomic Hybridization, DNA Copy Number Variations, Genome-Wide Association Study, Ubiquitin-Protein Ligases genetics, Autism Spectrum Disorder genetics, Schizophrenia
- Abstract
Aim: The present study aimed to examine the association between copy number variations (CNVs) in parkin (PRKN) and schizophrenia (SCZ) and autism spectrum disorder (ASD) in a large case-control sample., Method: Array comparative genomic hybridization was performed on 3111 cases with SCZ, 1236 cases with ASD, and 2713 controls. We systematically prioritized likely pathogenic CNVs (LP-CNVs) in PRKN and examined their association with SCZ and ASD., Results: In total, 3014 SCZ cases (96.9%), 1205 ASD cases (97.5%), and 2671 controls (98.5%) passed quality control. We found that monoallelic carriers of LP-CNVs in PRKN were common (70/6890, 1.02%) and were not at higher risk of SCZ (p = 0.29) or ASD (p = 0.72). We observed that the distribution pattern of LP-CNVs in the Japanese population was consistent with those in other populations. We also identified a patient diagnosed with SCZ and early-onset Parkinson's disease carrying biallelic pathogenic CNVs in PRKN. The absence of Parkinson's symptoms in 10 other monoallelic carriers of the same pathogenic CNV further reflects the lack of effect of monoallelic pathogenic variants in PRKN in the absence of a second hit., Conclusion: The present findings suggest that monoallelic CNVs in PRKN do not confer a significant risk for SCZ or ASD. However, further studies to investigate the association between biallelic CNVs in PRKN and SCZ and ASD are warranted., (© 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.)
- Published
- 2024
- Full Text
- View/download PDF
39. Behavioral Dysfunctions Caused by Pyridoxamine Deficiency in Drosophila melanogaster.
- Author
-
Ueno K, Nohara I, Miyashita M, Itokawa M, Okado H, Arai M, and Saitoe M
- Subjects
- Animals, Male, Sleep physiology, Female, Sexual Behavior, Animal physiology, Sexual Behavior, Animal drug effects, Learning, Drosophila melanogaster, Glycation End Products, Advanced metabolism, Pyridoxamine pharmacology, Behavior, Animal, Longevity
- Abstract
Pyridoxamine (PM) is one of the natural vitamins B6 (VB6) and functions as an endogenous inhibitor for the formation of AGEs (advanced glycation end products). The AGEs are implicated in aging, diabetes, and various neuropsychiatric disease, including schizophrenia, Alzheimer's disease, and Parkinson's disease. However, it is unclear whether the absence of PM per se accumulates AGEs in vivo and causes behavioral dysfunctions. To address these points, we raised PM-deficient fruit flies, Drosophila melanogaster, with the sterilized defined medium. Flies reared in a PM-deficient medium accumulated AGEs and reduced lifespan, impaired gustatory response, sleep, courtship behavior, and olfactory learning. These results suggest that PM suppresses AGE accumulation in vivo and is required for regulating innate and empirical behaviors.
- Published
- 2024
- Full Text
- View/download PDF
40. Glucuronic acid is a novel source of pentosidine, associated with schizophrenia.
- Author
-
Toriumi K, Iino K, Ozawa A, Miyashita M, Yamasaki S, Suzuki K, Sugawa H, Tabata K, Yamaguchi S, Usami S, Itokawa M, Nishida A, Nagai R, Kamiguchi H, and Arai M
- Subjects
- Humans, Glycation End Products, Advanced metabolism, Glucuronic Acid, Arginine metabolism, Lysine metabolism, Schizophrenia genetics
- Abstract
Pentosidine (PEN) is an advanced glycation end-product (AGEs), where a fluorescent cross-link is formed between lysine and arginine residues in proteins. Accumulation of PEN is associated with aging and various diseases. We previously reported that a subpopulation of patients with schizophrenia showed PEN accumulation in the blood, having severe clinical features. PEN is thought to be produced from glucose, fructose, pentoses, or ascorbate. However, patients with schizophrenia with high PEN levels present no elevation of these precursors of PEN in their blood. Therefore, the molecular mechanisms underlying PEN accumulation and the molecular pathogenesis of schizophrenia associated with PEN accumulation remain unclear. Here, we identified glucuronic acid (GlcA) as a novel precursor of PEN from the plasma of subjects with high PEN levels. We demonstrated that PEN can be generated from GlcA, both in vitro and in vivo. Furthermore, we found that GlcA was associated with the diagnosis of schizophrenia. Among patients with high PEN, the proportion of those who also have high GlcA is 25.6%. We also showed that Aldo-keto reductase (AKR) activity to degrade GlcA was decreased in patients with schizophrenia, and its activity was negatively correlated with GlcA levels in the plasma. This is the first report to show that PEN is generated from GlcA. In the future, this finding will contribute to understanding the molecular pathogenesis of not only schizophrenia but also other diseases with PEN accumulation., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper, (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
41. Association between enhanced carbonyl stress and decreased apparent axonal density in schizophrenia by multimodal white matter imaging.
- Author
-
Son S, Arai M, Toriumi K, Andica C, Matsuyoshi D, Kamagata K, Aoki S, Kawashima T, Kochiyama T, Okada T, Fushimi Y, Nakamoto Y, Kobayashi Y, Murai T, Itokawa M, and Miyata J
- Subjects
- Humans, Pyridoxal, Glycation End Products, Advanced, Axons, Schizophrenia diagnostic imaging, White Matter diagnostic imaging
- Abstract
Carbonyl stress is a condition featuring increased rich reactive carbonyl compounds, which facilitate the formation of advanced glycation end products including pentosidine. We previously reported the relationship between enhanced carbonyl stress and disrupted white matter integrity in schizophrenia, although which microstructural component is disrupted remained unclear. In this study, 32 patients with schizophrenia (SCZ) and 45 age- and gender-matched healthy volunteers (HC) were recruited. We obtained blood samples for carbonyl stress markers (plasma pentosidine and serum pyridoxal) and multi-modal magnetic resonance imaging measures of white matter microstructures including apparent axonal density (intra-cellular volume fraction (ICVF)) and orientation (orientation dispersion index (ODI)), and inflammation (free water (FW)). In SCZ, the plasma pentosidine level was significantly increased. Group comparison revealed that mean white matter values were decreased for ICVF, and increased for FW. We found a significant negative correlation between the plasma pentosidine level and mean ICVF values in SCZ, and a significant negative correlation between the serum pyridoxal level and mean ODI value in HC, regardless of age. Our results suggest an association between enhanced carbonyl stress and axonal abnormality in SCZ., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
42. Feasibility and Safety of Super Energy-dense Oral Nutritional Supplementation in Postoperative Gastric Cancer Patients.
- Author
-
Furuta R, Hatao F, Itokawa M, Yamazaki R, Morikawa Y, Honda M, Imamura K, Ishibashi Y, and Morita Y
- Abstract
Background/aim: Ensuring that postoperative gastric cancer patients receive sufficient oral nutritional supplementation (ONS) to prevent body weight loss (BWL) is a serious challenge. The present pilot study evaluated the feasibility and safety of small, frequent sip feeds (SIP) with super energy-dense ONS (SED ONS; 4 kcal/ml) in postoperative gastric cancer patients., Patients and Methods: Patients received 400 kcal/day of SED ONS in four, daily, 25 ml SIP for 12 weeks after gastrectomy. The primary outcome was the percentage of postoperative weight change. The expected mean weight change was 90% (10% standard deviation). A sample population of 14 patients, sufficient for a 95% confidence interval with a 10% margin of error, was enrolled., Results: The mean weight change for patients receiving SIP with SED ONS was 93.8%. The mean SED ONS intake was 348 kcal/day. Thirteen patients consumed more than 200 kcal/day of SED ONS. One patient with a mean intake of 114 kcal/day had undergone total gastrectomy followed by adjuvant chemotherapy., Conclusion: Small, frequent SIP with SED ONS was found to be feasible and safe in postoperative gastric cancer patients. A multicenter randomized controlled trial is warranted to determine whether SIP with SED ONS is effective in preventing BWL., Competing Interests: There are no potential conflicts of interest relevant to this article., (Copyright 2023, International Institute of Anticancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
43. Structural aging of human neurons is opposite of the changes in schizophrenia.
- Author
-
Mizutani R, Saiga R, Yamamoto Y, Uesugi M, Takeuchi A, Uesugi K, Terada Y, Suzuki Y, De Andrade V, De Carlo F, Takekoshi S, Inomoto C, Nakamura N, Torii Y, Kushima I, Iritani S, Ozaki N, Oshima K, Itokawa M, and Arai M
- Subjects
- Humans, Aging, Hallucinations, Neurites, Brain, Schizophrenia
- Abstract
Human mentality develops with age and is altered in psychiatric disorders, though their underlying mechanism is unknown. In this study, we analyzed nanometer-scale three-dimensional structures of brain tissues of the anterior cingulate cortex from eight schizophrenia and eight control cases. The distribution profiles of neurite curvature of the control cases showed a trend depending on their age, resulting in an age-correlated decrease in the standard deviation of neurite curvature (Pearson's r = -0.80, p = 0.018). In contrast to the control cases, the schizophrenia cases deviate upward from this correlation, exhibiting a 60% higher neurite curvature compared with the controls (p = 7.8 × 10-4). The neurite curvature also showed a correlation with a hallucination score (Pearson's r = 0.80, p = 1.8 × 10-4), indicating that neurite structure is relevant to brain function. This report is based on our 3D analysis of human brain tissues over a decade and is unprecedented in terms of the number of cases. We suggest that neurite curvature plays a pivotal role in brain aging and can be used as a hallmark to exploit a novel treatment of schizophrenia., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Masanari Itokawa and Makoto Arai declare a competing interest, being authors of patents regarding therapeutic use of pyridoxamine for schizophrenia. The patent title is "Detection and treatment of schizophrenia" (US-2014335517-A1, JP 5288365, and EP 2189537). This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors declare no competing interest., (Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.)
- Published
- 2023
- Full Text
- View/download PDF
44. Impact of super energy-dense oral nutritional supplementation (SED ONS) on glycemic variability and food intake postoperatively in gastric cancer patients.
- Author
-
Yamazaki R, Hatao F, Itokawa M, Morikawa Y, Honda M, Imamura K, Ishibashi Y, Furuta R, and Morita Y
- Subjects
- Humans, Blood Glucose Self-Monitoring adverse effects, Blood Glucose, Eating, Dietary Supplements, Stomach Neoplasms surgery, Stomach Neoplasms complications, Malnutrition etiology, Hypoglycemia
- Abstract
Purpose: Adherence to oral nutritional supplements (ONS) to prevent weight loss after gastrectomy is problematic. The present study evaluated the impact of super energy-dense ONS (SED ONS; 4 kcal/mL) on glycemic change and energy intake after gastrectomy., Methods: Gastrectomy patients were placed on continuous glucose monitoring for a 3-day observation period after food intake had been stabilized postoperatively. In addition, they were given 0, 200, and 400 kcal/day of SED ONS on Days 1, 2, and 3, respectively. The primary outcome was the area under the curve < glucose 70 mg/dL (AUC < 70). The secondary outcomes were other indices of glucose fluctuation and the amount of food and SED ONS intake., Results: Seventeen patients were enrolled. The AUC < 70 did not differ significantly with or without SED ONS over the observation period. SED ONS did not cause postprandial hypoglycemia and prevented nocturnal hypoglycemia. The mean dietary intake did not change significantly during the observation period, and the total energy intake increased significantly according to the amount of SED ONS provided., Conclusion: SED ONS after gastrectomy increased the total energy intake without dietary reduction and it did not result in hypoglycemia., (© 2022. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
45. Urinary exosomal microRNAs as predictive biomarkers for persistent psychotic-like experiences.
- Author
-
Tomita Y, Suzuki K, Yamasaki S, Toriumi K, Miyashita M, Ando S, Endo K, Yoshikawa A, Tabata K, Usami S, Hiraiwa-Hasegawa M, Itokawa M, Kawaji H, Kasai K, Nishida A, and Arai M
- Abstract
Psychotic-like experiences (PLEs) occur occasionally in adolescence and mostly disappear with increasing age. Their presence, if persistent, is considered a robust risk factor for subsequent psychiatric disorders. To date, only a few biological markers have been investigated for persistent PLE prediction. This study identified urinary exosomal microRNAs that can serve as predictive biomarkers for persistent PLEs. This study was part of a population-based biomarker subsample study of the Tokyo Teen Cohort Study. A total of 345 participants aged 13 (baseline) and 14 (follow-up) years underwent PLE assessments by experienced psychiatrists using semi-structured interviews. We defined remitted and persistent PLEs based on longitudinal profiles. We obtained urine at baseline and the expression levels of urinary exosomal miRNAs were compared between 15 individuals with persistent PLEs and 15 age- and sex-matched individuals with remitted PLEs. We constructed a logistic regression model to examine whether miRNA expression levels could predict persistent PLEs. We identified six significant differentially expressed microRNAs, namely hsa-miR-486-5p, hsa-miR-199a-3p, hsa-miR-144-5p, hsa-miR-451a, hsa-miR-143-3p, and hsa-miR-142-3p. The predictive model showed an area under the curve of 0.860 (95% confidence interval: 0.713-0.993) for five-fold cross-validation. We found a subset of urinary exosomal microRNAs that were differentially expressed in persistent PLEs and presented the likelihood that a microRNA-based statistical model could predict them with high accuracy. Therefore, urine exosomal miRNAs may serve as novel biomarkers for the risk of psychiatric disorders., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
46. Plasma unconjugated bile acids as novel biomarker for schizophrenia.
- Author
-
Koike S, Miyaji Y, Suzuki K, Miyashita M, Itokawa M, Arai M, and Ogasawara Y
- Subjects
- Humans, Chenodeoxycholic Acid, Biomarkers, Plasma, Bile Acids and Salts, Schizophrenia diagnosis
- Abstract
In this study, we measured conjugated and unconjugated free bile acids (BAs) in plasma from patients with schizophrenia and healthy subjects to examine the possibility of BA as a biomarker for schizophrenia. Although the levels of each BA conjugate showed no significant differences, significant differences for three unconjugated bile acids were observed in the plasma between patients with schizophrenia and healthy subjects. Additionally, a more than three times difference between patients and healthy subjects was observed in the mean value of the total concentrations of primary BAs. These results indicate that cholic acid and chenodeoxycholic acid levels in plasma may be novel diagnostic markers for a sub-population of patients with schizophrenia. Thus, future studies should elucidate the relationship between this increase in BA levels and the pathology of schizophrenia and verify the potential of unconjugated BA in plasma as biomarkers for schizophrenia., Competing Interests: Declaration of competing interest There is no conflict of interest., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
47. Betaine supplementation improves positive symptoms in schizophrenia.
- Author
-
Kirihara K, Fujioka M, Suga M, Kondo S, Ichihashi K, Koshiyama D, Morita K, Ikegame T, Tada M, Araki T, Jinde S, Taniguchi K, Hosokawa T, Sugishita K, Dogan S, Marumo K, Itokawa M, and Kasai K
- Subjects
- Humans, Methionine, Dietary Supplements, Homocysteine, Betaine therapeutic use, Schizophrenia drug therapy
- Abstract
Competing Interests: Declaration of competing interest The authors declare no conflict of interest in relation to this study.
- Published
- 2022
- Full Text
- View/download PDF
48. The difference in the diaphragmatic physiological measures between inspiratory and expiratory phases in ALS.
- Author
-
Morishima R, Shimizu T, Ishizaka Y, Kimura H, Bokuda K, Takahashi K, and Itokawa M
- Subjects
- Humans, Phrenic Nerve, Vital Capacity physiology, Ultrasonography, Diaphragm diagnostic imaging, Amyotrophic Lateral Sclerosis diagnostic imaging
- Abstract
Introduction: We aimed to clarify the differences in static and dynamic diaphragm parameters between the expiratory and inspiratory phases in amyotrophic lateral sclerosis (ALS)., Methods: Twenty patients with early-stage ALS and 16 healthy controls were enrolled in the study. We measured the amplitudes of compound muscle action potential (phCMAP) by electrical stimulation of the phrenic nerve and the zone of apposition wall thickness of the diaphragm (DT) using ultrasonography. We analyzed the differences in phCMAP (∆phCMAP) and DT (∆DT) between the end-inspiratory and end-expiratory phases and their correlation with forced vital capacity (FVC)., Results: The ΔphCMAP (mean 129.7 ± SD 204.7 µV) and ∆DT (0.80 ± 0.88 cm) in patients were significantly smaller than those in controls (348.6 ± 247.7 µV, p = 0.0003 and 1.89 ± 1.10 cm, p = 0.0002, respectively). Although ∆DT was significantly correlated with FVC, we found no correlation between ∆phCMAP and FVC. The phCMAP was paradoxically smaller during inspiration than during expiration in 35% of patients but in none of the controls., Conclusion: Dynamic parameters of the diaphragm were abnormal in early-stage ALS. The paradoxical reduction in phCMAP during inspiration may reflect early respiratory dysfunction. Assessment of dynamic abnormalities of the diaphragm may provide helpful information for respiratory management in patients with ALS., (© 2022. Fondazione Società Italiana di Neurologia.)
- Published
- 2022
- Full Text
- View/download PDF
49. Hair zinc levels and psychosis risk among adolescents.
- Author
-
Tabata K, Miyashita M, Yamasaki S, Toriumi K, Ando S, Suzuki K, Endo K, Morimoto Y, Tomita Y, Yamaguchi S, Usami S, Itokawa M, Hiraiwa-Hasegawa M, Takahashi H, Kasai K, Nishida A, and Arai M
- Abstract
Recent meta-analyses have shown lower zinc and higher copper levels in the serum of people with schizophrenia than in healthy controls. However, the relationship between trace elements (TEs) and the pathophysiology of psychosis, including schizophrenia, remains unclear due to the antipsychotic effects on mineral levels. In this study, we aimed to determine the relationship between zinc and copper levels in hair and psychosis risk among drug-naïve adolescents. This study was conducted as a part of a population-based biomarker subsample study of the Tokyo Teen Cohort Study, including 252 community-dwelling 14-year-old drug-naïve adolescents. Zinc and copper levels in hair were measured using inductively coupled plasma mass spectrometry. The thought problems (TP) scale from the Child Behavior Checklist was used to evaluate psychosis risk. Regression analysis showed that hair zinc levels were negatively correlated with the TP scale (T-score) (β = -0.176, P = 0.005). This result remained significant after adjusting for age and sex (β = -0.175, P = 0.005). In contrast, hair copper levels were not associated with the TP scale (T-score) (β = 0.026, P = 0.687). These findings suggest that lower zinc levels could be involved in the pathophysiology of psychosis, independent of antipsychotics. Further longitudinal studies are required to investigate whether hair zinc level is a useful new biomarker for assessing psychosis risk., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
50. Relationship between cleft palate width and otitis media.
- Author
-
Yoshitomi A, Baba S, Tamada I, Nakaya M, and Itokawa M
- Abstract
Objectives: To investigate the relationship between cleft width and otitis media (OM) and to determine whether a wide cleft palate (CP) is a risk factor of the incidence, type, amount of middle ear effusion, and prolonged morbidity in OM., Study Design: Retrospective cohort study., Methods: Children with CP who underwent palatoplasty between 2014 and 2018 were analyzed. Cleft width was measured at palatoplasty. The incidence of otitis media with effusion (OME) and acute otitis media (AOM), the type and amount of middle ear effusion, and OME duration and age at resolution were assessed in relation to cleft width., Results: One hundred eighteen children were included. The CP types were Veau I in 16, II in 35, III in 48, and IV in 19 patients. The incidence of OME and AOM before palatoplasty was 83.1% and 49.2%, respectively. Cleft width did not differ significantly between patients with or without OME but was significantly greater in those with, than in those without, AOM ( p < .001), in those with mucoid, than in those with serous, effusion ( p = .012), and in those with complete, than in those with partial, effusion ( p = .01). Regardless of cleft width or type, OME persisted for a median duration of 50 months., Conclusions: Cleft width was significantly associated with the incidence of AOM and the type and amount of middle ear effusion before palatoplasty. However, it was not significantly related to the incidence, age at resolution, or duration of OME. Regardless of cleft width or type, OM in children with CP requires long-term follow-up. Level of Evidence: 2b., Competing Interests: The authors have no conflicts of interest to disclose., (© 2022 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.